Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.67 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Open
$0.67
Previous Close
$0.67
Day High
$0.67
Day Low
$0.64
52 Week High
08/5/14 - $2.25
52 Week Low
05/21/15 - $0.30
Market Cap
34.6M
Average Volume 10 Days
28.5K
EPS TTM
$-0.12
Shares Outstanding
51.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENUMERAL BIOMEDICAL HOLDINGS (ENUM)

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of F...
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. to Amend Certificate of Incorporation

Enumeral Biomedical Holdings, Inc. announced at the AGM to be held on June 18, 2015, it will propose to grant the board of directors discretionary authority to amend the company's certificate of incorporation to effectuate a reverse stock split of the company's Common Stock, $0.001 par value, by a ratio of no less than one-for-five and no more than one-for-fifteen with such ratio to be determined by the board in its sole discretion and with such Reverse Split to be effective at such time and date, if at all, as determined by the board in its sole discretion, it being understood that the purpose of such Reverse Split is to attempt to obtain a listing on either The Nasdaq Capital Market or the NYSE MKT.

Enumeral Biomedical Holdings, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Enumeral Biomedical Holdings, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company’s revenue was $274,722 compared to $50,714 a year ago. This increase in revenue is primarily attributable to the Company’s collaboration agreement with Merck. Loss from operations was $2,380,725 compared to $1,138,775 a year ago. Net income before income taxes was $2,291,794 compared to net loss before income taxes of $1,190,476 a year ago. Net income was $2,291,794 compared to net loss of $1,190,476 a year ago. Basic and diluted income per common share was $0.04 compared to basic and diluted loss per common share of $0.07 a year ago. This increase in net income was primarily due to gain of $4,669,884 from the change in the fair value of the Company’s warrant liability, offset by an increase of $1,465,958 in research and development and general and administrative expenses.

Enumeral Biomedical Holdings, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM

Enumeral Biomedical Holdings, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM. Venue: Time Warner Center, New York, United States. Speakers: Derek Brand, Vice President of Business Development and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $0.67 USD 0.00

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies
 

Industry Analysis

ENUM

Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.1x
Price/Book 45.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.